Leerink Partnrs Has Positive Outlook of RXRX Q2 Earnings
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) – Analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for shares of Recursion Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($0.34) per share for the quarter, up […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) – Analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for shares of Recursion Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($0.34) per share for the quarter, up […]
